Navigation Links
Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer
Date:9/28/2007

(PHILADELPHIA) Scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have discovered new molecular evidence of the role of the hormone prolactin in breast cancer. They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new signaling pathway that may regulate the growth and survival of breast cancer cells.

The work, which appears this month in the journal Molecular Endocrinology, identifies the protein Jak1 as playing a key part in prolactin signaling in breast cancer. Jak1, which belongs to the cell growth-promoting tyrosine kinase class of enzymes, could represent a new drug target for treating breast cancer.

In breast cancer cells, we found that Jak1 not only stimulates conventional prolactin signaling via proteins such as Stat5, but also that Jak1 recruited new signals, especially Stat3 and ERK, says Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and principal investigator of the study. Because Stat3 and ERK typically are considered tumor-promoting, inhibitors of Jak1 may become useful in breast cancer treatment.

Receptors for prolactin, have previously been shown to promote breast cancer cell growth, survival, and differentiation, Dr. Rui explains, through signaling pathways that involve activation of such proteins as Stat5, ERK, and Akt. Prolactin is also known toactivate Stat3, which has been implicated as an oncogene involved in cancer cell growth and survival. In the current study, when Jak1 protein expression was experimentally disrupted in breast cancer cells, prolactin signaling through Stat3 and ERK was completely blocked. Signaling through Stat5 and Akt was reduced but still present.

Until now, prolactin was believed to signal only through Jak2 to mediate its effects, says Lynn Neilson, Ph.D., a postdoctoral fellow in the Department of Cancer Biology at Jefferson Medical College and first author of the study. The unexpected finding that prolactin also activates Jak1 in breast cancer points to a mechanism in cancer cells that further promotes tumor cell growth.

Dr. Ruis laboratory currently is seeking to determine the role of Jak1 in breast cancer cell growth, survival, and invasion, which will be important for establishing the potential usefulness of Jak1 as a new drug target in patients. Prolactin is secreted by the pituitary gland, and important for milk production during lactation. Receptors for this hormone are present on a majority of breast cancers. Prolactin levels in blood are relatively unaffected by menopause, and breast cancer patients are exposed to the hormone across all age groups.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson Physicians Report on Potentially Fatal Complication of Heart Attack
2. Jefferson Researchers Want to Learn If Heart Defect at Heart of Some Migraines
3. Researchers urge caution in using ear tube surgery
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Researchers identify the early makers of Neonatal Sepsis
6. OHSU Researchers Announce New Discovery
7. Researchers Identify Gene Connected To Bipolar Disorder
8. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. Gene researchers make Malaria-resistant mosquito
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: